Abbott has obtained CE-Mark for the new generation of its everolimus-eluting XIENCE coronary stent system, allowing the sale of the device for patients with heart disease in Europe.

The new design, delivery system and size of the new XIENCE Sierra stent are intended to improve the ability to access and unblock clogged arteries in complicated cases.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

XIENCE Sierra features a thinner profile, enhanced flexibility, longer lengths and small-diameters, enabling doctors to use less force during implantation of the stent.

Abbott vascular business senior vice-president Chuck Brynelsen said: “Doctors tell us they need better tools to treat increasingly challenging cases, which involve multiple or totally blocked arteries and complications such as diabetes.

“We designed XIENCE Sierra with the goal of helping more people with coronary artery disease regain their health and return to their daily lives as quickly as possible.”

“We designed XIENCE Sierra with the goal of helping more people with coronary artery disease regain their health and return to their daily lives.”

The efficacy and safety of XIENCE coronary stent is said to be supported by ten years of real-world experience and data from more than 100 clinical trials.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Abbott has already submitted an application to the US Food and Drug Administration (FDA) for the approval of XIENCE Sierra.

Earlier this month, the firm obtained FDA clearance for its Confirm Rx insertable cardiac monitor (ICM) for remote monitoring and detection of cardiac arrhythmias, including irregular heartbeats.

The smartphone-compatible ICM uses wireless Bluetooth technology to transmit data and requires a rapid and minimally invasive procedure for implantation.

Following the download of a related mobile application on the patient’s smartphone, physicians can continuously monitor and record episodes of irregular heartbeats.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact